Genetic Causes and Modifiers of Autism Spectrum Disorder.

Rylaarsdam L, Guemez-Gamboa A. · 2019

Read Genetic Causes and Modifiers of Autism Spectrum Disorder. by Rylaarsdam L, Guemez-Gamboa A. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6710438.txt.

Introduction

Rylaarsdam and Guemez-Gamboa review the genetics of autism spectrum disorder. Autism affects an estimated 1 in 59 children. Its causes are largely genetic, but they vary a great deal from person to person. Hundreds of genes have been tied to the condition so far.

Known genes still explain only about 10 to 20 percent of cases. The review shows how extra genetic changes can soften or worsen the picture in each person. These modifiers include copied or missing DNA stretches, single-letter changes, and chemical marks on DNA. They can push brain wiring off course, and they may help explain why cases differ so much.

Catalog record

CREATORRylaarsdam L, Guemez-Gamboa A.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE97 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6710438

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Genetic Causes and Modifiers of Autism Spectrum Disorder By Lauren Rylaarsdam, Alicia Guemez-Gamboa Published in: Frontiers in Cellular Neuroscience DOI: 10.3389/fncel.2019.00385 ABSTRACT Autism Spectrum Disorder (ASD) is one of the most prevalent neurodevelopmental disorders, affecting an estimated 1 in 59 children. ASD is highly genetically heterogeneous and may be caused by both inheritable and de novo gene variations. In the past decade, hundreds of genes have been identified that contribute to the serious deficits in communication, social cognition, and behavior that patients often experience. However, these only account for 10–20% of ASD cases, and patients with similar pathogenic variants may be diagnosed on very different levels of the spectrum. In this review, we will describe the genetic landscape of ASD and discuss how genetic modifiers such as copy number variation, single nucleotide polymorphisms, and epigenetic alterations likely play a key role in modulating the phenotypic spectrum of ASD patients. We also consider how genetic modifiers can alter convergent signaling pathways and lead to impaired neural circuitry formation. Lastly, we review sex-linked modifiers and clinical implications. Further understanding of these mechanisms is crucial for both comprehending ASD and for developing novel therapies. INTRODUCTION Autism was first described by Kanner (1943) in a detailed report of 11 children with similar unusual tendencies. Intriguing common symptoms such as improper facilitation of language, indifference to other people, and obsessive interests can clearly be discerned while reading Kanner’s thorough patient history. Twenty-three years later, the first epidemiological study of autism estimated prevalence to be 4.5 per 10,000 individuals. Estimates have since increased drastically to 1 in 59 individuals affected, with at least three times as many males diagnosed as females (Loomes et al., 2017). This significant increase in prevalence is partially attributable to both increase in awareness and evolvement of Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria, from a childhood form of schizophrenia in 1952, to a core diagnosis covering a spectrum of disorders in the present (Zeldovich, 2018). The changing landscape of factors required for diagnosis makes it difficult to quantify the actual increase in prevalence. According to the current DSM-5 criteria, only two core features make up an autism spectrum disorder (ASD) diagnosis: (1) persistent deficits in social communication and social interaction across multiple contexts; and (2) restricted, repetitive patterns of behavior, interests, or activities (Lai et al., 2014). Because of the broad nature of these definitions, an ASD diagnosis often co-occurs with other conditions. Motor abnormalities (79%), gastrointestinal problems (up to 70%), epilepsy (up to 30%), intellectual disability (45%), and sleep disorders (50–80%) are common examples (Lai et al., 2014). Language disorders are frequently co-occurring and were even included in the DSM-IV criteria. Since autism’s identification as a diagnosis, the medical and scientific community have put immense effort into determining the risk factors and etiology. In Kanner’s original assessment, he makes the unfortunate observation that in addition to patients having highly intelligent parents, “One other fact stands out prominently. In the whole group, there are very few really warm-hearted fathers and mothers” (Kanner, 1943). Thankfully, this “Refrigerator Mother” theory of autism was quickly disproved. ASD is now understood to be a disease of complex interaction between genetics and the environment, with heritability estimates ranging from 40 to 80% (Chaste and Leboyer, 2012). Extensive genetic studies have revealed hundreds of genes linked to autism. Epidemiological investigations have begun to elucidate which environmental factors might be contributing to risk, but there is a lot left to understand about how they interact with genetic predisposition to contribute to ASD etiology. As is often the case with complex diseases, individuals with similar pathogenic variants may have drastically varying phenotypes. For example, people with duplications of proximal 15q range from unaffected to severely disabled (Cook et al., 1997; Bolton et al., 2001). Genetic modifiers – factors that modulate the expression of other genes – likely exist when individuals with the same pathogenic variant present on opposite ends of the spectrum. In this review, we will discuss what is presently known about the genetic landscape of ASD, then look at potential modifiers including copy number variation (CNV), double-hit mutations, epigenetic influences, and sex-linked effects. GENETICS OF ASD Identification of Candidate ASD Risk Genes Following the classification of autism by Kanner, research efforts were undertaken to determine the disease etiology. Though it was initially assumed to be of environmental origin, an improved understanding of the role of genetics in human health soon suggested otherwise. In 1977, Folstein and Rutter (1977) conducted twin studies upon the observation that incidence among siblings was 50× higher than average. They found that monozygotic twins were more likely to share a diagnosis than dizygotic twins, suggesting a genetic influence. Bailey et al. (1995) supported this finding, documenting 60% concordance for monozygotic twins versus no concordant dizygotic pairs. In addition, risk of a child having ASD was found to be proportional to the percentage of the genome they shared with an affected sibling or parent (Constantino et al., 2010; Risch et al., 2014; Sandin et al., 2014). By the turn of the century, ASD was established to have some genetic component, though which genes were involved remained a mystery. Early karyotype studies documenting chromosomal abnormalities began to shed light on which regions of the genome were involved (Gillberg and Wahlström, 1985). Additional susceptibility loci screens implicated regions on chromosome 7q, 1p, 3q, 16p, and 15q (IMGSAC, 1998; Barrett et al., 1999; Buxbaum et al., 2001; International Molecular Genetic Study of Autism Consortium [IMGSAC], 2001; Liu et al., 2001; Auranen et al., 2002; Lamb et al., 2002; Shao et al., 2003; Risch et al., 2014). However, to investigate at gene-level resolution, early studies had to use the candidate approach. Hypothesized targets included genes from suspected chromosomal regions that played a critical role in neurodevelopment, such as homeobox (Hox) family or Wnt genes. Unsurprisingly, many early studies using this method were largely inconclusive (Krebs et al., 2002; Lamb et al., 2002; Talebizadeh et al., 2002; Zhang et al., 2002). Starting in 2001, the candidate approach experienced moderate success with findings supporting reelin (RELN), aristaless related homeobox (Arx), methyl-CpG binding protein 2 (MeCP2), neuroligin 3 (NLGN3), neuroligin 4 (NLGN4), tuberous sclerosis complex 2 (TSC2), and ubiquitin protein ligase E3A (UBE3A)’s involvement in ASD etiology (Persico et al., 2001; Strømme et al., 2002; Carney et al., 2003; Jamain et al., 2003; Serajee et al., 2003; Jiang et al., 2004). In the early 2000s, the advent of high throughput sequencing revolutionized genetic research and enabled investigators to study ASD on a genome-wide level. Sequencing technology quickly confirmed that the etiology of ASD was multigenic and highly heterogeneous, with very few of the same pathogenic variants present in a significant percentage of afflicted individuals. It is now known that the average case is a product of many susceptibility-increasing variations. Only a handful of ASD-related diseases have monogenic causes, such as Rett syndrome, fragile X syndrome, tuberous sclerosis, and Schuurs–Hoeijmakers syndrome (Artuso et al., 2011; Stern et al., 2017; Woodbury-Smith and Scherer, 2018). Dozens of large-scale genetic studies have since been conducted on ASD patients and their families, leading to hundreds of risk genes being identified. While these proteins have diverse functions, a majority of reproducible hits come from two

Read the complete text